Disease
ORAL
COMPOUND
COMPOUND
Discovery
Preclinical
Phase 1
Phase 2
Sarcopenia
MF-300
MF-300 is a “first-in-class” sarcopenia therapy. Sarcopenia is a large unmet need with no FDA approved therapies.
Neuromuscular (SMA)
Not Disclosed
Fibrosis (IPF)
Not Disclosed